- EIB lends up to €100 million to Swedish medtech company Elekta AB.
- Elekta will invest approximately €200 million in research from 2026 to 2029, primarily in Sweden and the Netherlands.
- Research covers radiotherapy, radiosurgery, brachytherapy and treatment-planning software.
- Elekta treats over 2 million patients annually and operates in more than 120 countries.
EIB lends €100 million to Swedish cancer-treatment firm
The European Investment Bank (EIB) is lending up to €100 million to Stockholm-based medical-technology company Elekta AB. The loan will finance research and development in radiotherapy, radiosurgery, brachytherapy and software for treatment planning and delivery for patients with cancer and neurological conditions.
Research programme 2026-2029
Elekta plans to invest approximately €200 million in its research programme between 2026 and 2029. Most of the work will take place in Sweden and the Netherlands, with the EIB loan covering up to half of the investments.
The research programme includes:
- New radiotherapy, radiosurgery and brachytherapy systems
- Software for treatment planning, workflow automation and precision delivery
- Solutions to improve treatment accuracy and efficiency
Patient reach and global presence
Elekta develops technologies to treat illnesses including brain tumours, breast cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, essential tremor and certain forms of epilepsy. The company's radiotherapy treatments serve more than 2 million patients worldwide a year.
| Parameter | Value |
|---|---|
| EIB loan | Up to €100 million |
| Total research budget | Approx. €200 million |
| Period | 2026-2029 |
| Primary countries | Sweden and the Netherlands |
| Patients treated annually | Over 2 million |
| Countries with sales | More than 120 |
| Countries with operations | Approx. 40 |
| Employees | Approx. 4,000 |
Strategic significance for Europe
"Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here," said EIB Vice-President Karl Nehammer. "This financing will support the next generation of cancer and neurological treatments."
Elekta Chief Financial Officer Klara Eiritz stated:
"As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision. This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience."
The loan supports the EIB Group's TechEU programme to strengthen European investment in strategic technologies and innovation. It also contributes to European Union goals for health research, competitiveness and advanced medical technologies.
About the EIB Group
The EIB Group is the financing arm of the European Union, owned by the 27 Member States, and one of the largest multilateral development banks in the world. In 2025, the EIB Group signed €100 billion in new financing and advisory services for over 870 projects under eight core priorities supporting EU policy objectives.
See EIB key figures and EIB core strategic priorities for further information.
Elekta is listed on Nasdaq Stockholm and has offices in more than 40 countries. Learn more about Elekta